PB0743 - Different occurrence of platelet-monocyte aggregates (PMA) in patients with different metabolic diseases and effect of direct anticoagulants

Monday, June 24, 2024

13:45 – 14:45 ICT

Room: Exhibition Hall

Presenting Author(s)

Alejandro Carazo, PharmD PhD

Assistant professor
Charles University, Faculty Of Pharmacy
Hradec Králové, Kralovehradecky kraj, Czech Republic

Co-Author(s)

LK

Lukáš Konečný

PhD student
Charles University, Faculty Of Pharmacy
Hradec Králové, Kralovehradecky kraj, Czech Republic
JF

Jaka Fadraersada

PhD student
Charles University, Faculty Of Pharmacy
Hradec Králové, Kralovehradecky kraj, Czech Republic
RA

Raúl Alva-Gallegos

PhD student
Charles University, Faculty Of Pharmacy
Hradec Králové, Kralovehradecky kraj, Czech Republic
PS

Pavel Skořepa

MD
University Hospital Hradec Králové
Hradec Králové, Kralovehradecky kraj, Czech Republic
KM

Kateřina Matoušová

Assistant professor
University Hospital Hradec Králové
Hradec Kralove, Kralovehradecky kraj, Czech Republic
LK

Lenka Krčmová

Associate professor
Charles University, Faculty Of Pharmacy
Hradec Kralove, Kralovehradecky kraj, Czech Republic
MP

Markéta Paclíková

MD
University Hospital Hradec Králové
Hradec Kralove, Kralovehradecky kraj, Czech Republic
MB

Milan Blaha

MD
University Hospital Hradec Králové
Hradec Kralove, Kralovehradecky kraj, Czech Republic
VB

Vladimir Blaha

MD
University Hospital Hradec Králové
Hradec Kralove, Kralovehradecky kraj, Czech Republic
PM

Přemysl Mladěnka

Professor
Charles University, Faculty Of Pharmacy
Hradec Kralove, Kralovehradecky kraj, Czech Republic

Background: Platelet-monocyte aggregates (PMA) are possible novel biomarkers of early onset of cardiovascular diseases. For PMAs formation, circulating platelets need to be activated. However, the extent of PMAs generation varies probably among particular diseases and other characteristics of individual patients. Additionally, pharmacotherapy might affect their formation.

Aims: The aims of the study was to: 1) analyse the occurrence of PMA and activated platelets in different groups of patients and compare them to that of healthy donors; 2) evaluate the effect of direct anticoagulants on PMA occurrence and 3) study correlations between PMA and biochemical parameters.

Methods: Individuals presenting different metabolic diseases (15 patients with familial hypercholesterolemia - FH, 50 with DM type I – DMT1, and 50 with metabolic syndrome - MS) were enrolled in this study. As control group, 50 healthy volunteers were recruited. PMAs were labelled in freshly withdrawn blood (CD41 for platelets, CD14 for monocytes and CD45 as a pan-leukocyte marker) and analyzed by flow cytometry. Activated platelets were labelled with CD41 and CD62P. In a separate set of experiments, blood was also treated with anticoagulants.

Results: PMA occurrence in enrolled patients (20% for FH; 48% for DM T1; 40% for MS) was higher than in healthy volunteers (15%). Regarding activated platelets, the result mostly correlated with that of PMAs except for those of FH, in which the number of activated platelets was even lower than in healthy donors. This result is probably due to the intensive pharmacological treatment these patients undergo. After in vitro anticoagulant treatment, the mean percentage of PMAs was decreased in all groups. However, the reduction was variable depending on the disease. Additionally, differences among anticoagulants groups (antiFII or anti-FXa) were also observed.

Conclusion(s): PMA occurrence is significantly increased in patients suffering from metabolic disorders compared to healthy volunteers. Modern anticoagulants might decrease the occurrence of these biomarkers.